ArticleMedicine2026
Magnesium depletion score and erectile dysfunction: A cross-sectional and Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erectile dysfunction (ED) is closely linked to vascular and metabolic disorders. Magnesium plays a crucial role in endothelial function, inflammation, and metabolism, but the relevance of chronic magnesium depletion to ED remains unclear. The magnesium depletion score (MDS) is a practical marker of long-term magnesium loss. This study examined the association between MDS and ED in United States adults and explored genetic evidence for magnesium metabolism using Mendelian randomization (MR). This cross-sectional study included 3692 men aged ≥ 20 years from National Health and Nutrition Examination Survey 2001 to 2004. MDS was calculated from renal function, diuretic and proton-pump inhibitor use, and alcohol consumption. Survey-weighted logistic regression, subgroup analysis, and restricted cubic splines were used to evaluate the association between MDS and ED, adjusting for demographic, lifestyle, and metabolic factors. Two-sample and multivariable MR analyses assessed genetic evidence for the relationship between magnesium metabolism disorders and ED, with adjustment for body mass index (BMI), type 2 diabetes, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol. Higher MDS was associated with increased odds of ED (fully adjusted odds ratio = 1.40; 95% confidence interval, 1.22-1.61; P = .002). Men with MDS ≥ 2 had more than twice the odds of ED compared with those with MDS < 2. Restricted cubic spline analysis demonstrated a nonlinear relationship, with the risk beginning to rise at approximately an MDS of 1 and increasing sharply when the MDS exceeded 3. Two-sample MR found no direct causal effect of magnesium metabolism disorders on ED. In multivariable MR, magnesium metabolism disorders showed a modest positive association with ED after adjustment for BMI, diabetes, and lipid traits (odds ratio = 1.01; 95% confidence interval, 1.00-1.02; P = .028). Genetically predicted higher BMI and diabetes were also associated with ED. Higher MDS was associated with increased odds of ED in United States adult men. MR findings provided limited but supportive evidence for a role of magnesium metabolism within a broader cardiometabolic context. Overall, MDS may serve as a potential risk marker for ED, but further prospective and interventional studies are needed to confirm its clinical relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.